ReviewHNO2026
[Chances and challenges in the prevention and treatment of early childhood hearing loss: the AWMF guideline on congenital CMV infection].
Review in HNO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After genetic causes, congenital cytomegalovirus (cCMV) infection is the leading infectious cause of congenital and early childhood hearing loss. The 2025 German S2k guideline on prevention, diagnosis, and treatment of CMV infection in pregnant women and congenital CMV infection in neonates and children published by the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF; 093-003 [24]) provides corresponding recommendations and summarizes the current evidence. Hygiene counseling of pregnant women, targeted diagnostic testing during pregnancy and in neonates, and antiviral therapeutic options are important measures for prevention and treatment of congenital CMV infection. Universal newborn hearing screening (UNHS) is decisive for the diagnosis of congenital hearing loss. If abnormal results are revealed in the initial and follow-up testing, polymerase chain reaction (PCR) analysis of CMV DNA in urine (gold standard) or saliva should be performed immediately-as it should be in the case of other symptoms-preferably in the maternity or pediatric hospital and certainly not later than in the second to third week of life. In the case of symptomatic congenital CMV infection, causal treatment of congenital hearing loss can be offered as early as during the first 30 days of life-both for clinically symptomatic infants and for those with isolated hearing loss. Treatment may reduce the severity of hearing loss, stabilize hearing, or prevent progression. Long-term aftercare is essential to recognize progression or a late onset of hearing loss and to ensure adequate management. In addition to dissemination of these guideline recommendations, interdisciplinary cooperation-particularly between the maternity and neonatal departments performing UNHS and otorhinolaryngology and pediatric audiology departments-is essential.
Indexed as
Identifiers
42867519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.